AZD2281 Olaparib (kuDOS/LynparzaTM, AstraZeneca), used for oral administration, is the first inhibitor identified as single antitumoral agent in cancer associated with the BRCA1 or BRCA2 mutations [93, 94]. Here, BRCA1 is linked to cancer.